Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects

Biochemistry (Mosc). 2018 Sep;83(9):1057-1067. doi: 10.1134/S0006297918090079.

Abstract

Drug development for the treatment of Alzheimer's disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / immunology
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Cholinesterase Inhibitors / metabolism
  • Cholinesterase Inhibitors / therapeutic use
  • Humans
  • Peptides / chemistry
  • Peptides / metabolism
  • Peptides / therapeutic use
  • Receptors, Nicotinic / chemistry
  • Zinc / chemistry
  • Zinc / metabolism

Substances

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal
  • Cholinesterase Inhibitors
  • Peptides
  • Receptors, Nicotinic
  • nicotinic acetylcholine receptor alpha4 subunit
  • Zinc